As a selective monoamine oxidase B (MAO-B) inhibitor, XADAGO offers a unique mechanism of action that complements traditional therapies, potentially improving motor function and reducing 'off' time in patients. The increasing prevalence of Parkinson's disease and the growing demand for effective therapies create a substantial market opportunity for XADAGO, particularly in regions with aging populations..

作为一种选择性单胺氧化酶B（MAO-B）抑制剂，XADAGO提供了独特的机制，补充了传统疗法，可能改善运动功能并减少患者的“关闭”时间。帕金森病患病率的增加以及对有效疗法需求的增长，为XADAGO创造了巨大的市场机会，尤其是在老龄化人口较多的地区。

LAS VEGAS

拉斯维加斯

,

，

April 22, 2025

2025年4月22日

/PRNewswire/ -- DelveInsight's '

/PRNewswire/ -- DelveInsight的

XADAGO/EQUFINA Market Size, Forecast, and Market Insight Report

XADAGO/EQUFINA市场规模、预测和市场洞察报告

' highlights the details around XADAGO/EQUFINA, an inhibitor of monoamine oxidase B (MAO-B) indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of XADAGO/EQUFINA.

重点介绍了XADAGO/EQUFINA的详细信息，这是一种单胺氧化酶B（MAO-B）抑制剂，作为左旋多巴/卡比多巴的辅助治疗药物，用于治疗经历“关闭”期的帕金森病患者。报告提供了XADAGO/EQUFINA的产品描述、专利细节以及竞争产品（已上市和新兴疗法）的信息。

The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [.

该报告还重点介绍了2020年至2034年按7MM[分段的历史和预测销售额。

the United States

美国

, the EU4 (

，欧盟4（

Germany

德国

,

，

France

法国

,

，

Italy

意大利

, and

，以及

Spain

西班牙

), the

)，则

United Kingdom

英国

, and

，以及

Japan

日本

].

].

Newron Pharmaceuticals/Eisai/Meiji Seika Pharma's XADAGO/EQUFINA (safinamide) Overview

新隆制药/卫材/明治制果药业的XADAGO/EQUFINA（沙非酰胺）概述

XADAGO is a monoamine oxidase B (MAO-B) inhibitor used alongside levodopa/carbidopa to help manage 'off' episodes in individuals with Parkinson's disease. While its exact mode of action in treating Parkinson's is not fully understood, it is thought to work by inhibiting MAO-B, thereby reducing dopamine breakdown.

XADAGO是一种单胺氧化酶B（MAO-B）抑制剂，与左旋多巴/卡比多巴联合使用，有助于管理帕金森病患者的“关闭”期。虽然其治疗帕金森病的确切作用机制尚未完全了解，但一般认为它通过抑制MAO-B减少多巴胺的分解来发挥作用。

This leads to increased dopamine levels and enhanced dopaminergic activity in the brain. XADAGO contains the active ingredient safinamide in the form of a mesylate salt and is available in 50 mg and 100 mg film-coated oral tablets. Each tablet provides either 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg of the safinamide base.

这会导致大脑中多巴胺水平升高以及多巴胺能活动增强。XADAGO 含有活性成分甲磺酸沙非酰胺，有 50 毫克和 100 毫克薄膜包衣口服片剂两种规格。每片分别提供 65.88 毫克或 131.76 毫克的甲磺酸沙非酰胺，相当于 50 毫克或 100 毫克的沙非酰胺碱基。

The medication is marketed as XADAGO in .

该药物以XADAGO为名在市场上销售。

the United States

美国

and

和

Europe

欧洲

and under the name EQUFINA in

并以EQUFINA名称

Japan

日本

.

。

Drug Name

药品名称

XADAGO/EQUFINA (safinamide)

XADAGO/EQUFINA（沙非酰胺）

Developer

开发者

Newron Pharmaceuticals/Eisai/Meiji Seika Pharma

Newron Pharmaceuticals/Eisai/明治制果药业

Approval Year

批准年份

2017 (US);  2015 (EU); 2019 (JP)

2017年（美国）；2015年（欧盟）；2019年（日本）

Primary Indication

主要适应症

Parkinson's disease

帕金森病

Mechanism of action

作用机制

MAO-B inhibitor

单胺氧化酶B抑制剂

Route of administration

给药途径

Oral

口服

Learn more about XADAGO/EQUFINA projected market size for Parkinson's disease @

了解有关帕金森病的XADAGO/EQUFINA预计市场规模的更多信息 @

XADAGO/EQUFINA Market Potential

XADAGO/EQUFINA市场潜力

Parkinson's disease is a progressive neurological disorder that mainly impairs movement control. It results from the slow degeneration of dopamine-producing neurons in the brain, especially in the substantia nigra, a region crucial for managing voluntary motor function. According to estimates by DelveInsight, there were .

帕金森病是一种进行性神经系统疾病，主要损害运动控制能力。它是由大脑中产生多巴胺的神经元逐渐退化所致，尤其是在管理随意运动功能至关重要的黑质区域。根据DelveInsight的估计，存在 。

2.7 million

270万

diagnosed prevalent cases of Parkinson's disease in the 7MM in 2023, with

2023年在7MM中诊断出的帕金森病流行病例，伴随

the United States

美国

accounting for around

约占

45%

45%

of these cases. While a cure for Parkinson's remains elusive, a combination of pharmacological and non-pharmacological therapies is used to manage symptoms. Physical, occupational, and speech therapies form key components of treatment, and surgical procedures may benefit select patients. Additionally, complementary therapies are sometimes employed to help address particular symptoms..

这些病例。虽然帕金森病的治愈方法仍然难以捉摸，但通常会采用药物和非药物疗法相结合的方式来控制症状。物理治疗、职业治疗和语言治疗是治疗的关键组成部分，外科手术可能使部分患者受益。此外，有时也会采用辅助疗法来帮助应对特定症状。

Frequently prescribed medications for Parkinson's include

帕金森病常用的处方药物包括

levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A antagonists

左旋多巴、多巴胺激动剂、MAO-B抑制剂、COMT抑制剂、金刚烷胺、抗胆碱能药物和腺苷A2A拮抗剂

. These treatments primarily target motor symptoms, which are a major concern for those affected. DelveInsight reports that the Parkinson's disease market in the 7MM was valued at

。这些治疗主要针对运动症状，这是受影响人群最关心的问题。DelveInsight 报告称，七大市场（7MM）中的帕金森病市场估值为

USD 3.2 billion

32亿美元

in 2023. The market is expected to grow over the forecast period (2020–2034), fueled by the launch of new therapies, increasing prevalence, better access to healthcare, and rising demand for more advanced and effective treatment options.

在 2023 年。预计市场将在预测期内（2020-2034 年）增长，这得益于新疗法的推出、患病率的上升、医疗保健服务的更好获取以及对更先进和有效治疗方案需求的不断增长。

Discover more about the Parkinson's disease market in detail @

详细了解帕金森病市场的更多信息 @

Parkinson's Disease Market Report

帕金森病市场报告

Emerging Competitors of XADAGO/EQUFINA

XADAGO/EQUFINA的新兴竞争对手

Some of the drugs in the pipeline include

一些正在研发中的药物包括

Solengepras

索伦格拉斯

(Cerevance),

(Cerevance),

Minzasolmin

明扎索尔敏

(UCB Biopharma SRL/Novartis),

(UCB生物制药有限公司/诺华),

Buntanetap

布塔内塔普

(Annovis Bio), and others.

(Annovis Bio)，以及其他。

Buntanetap

布塔内塔普

has successfully completed Phase III trials for early-stage Parkinson's disease. Annovis Bio has scheduled a meeting with the FDA in Q1 2025 to determine the development path forward for Buntanetap in the treatment of Parkinson's disease. Buntanetap is also being developed for Alzheimer's disease, Lewy Body Dementia, and other neurodegenerative disorders..

针对早期帕金森病的III期试验已成功完成。Annovis Bio计划在2025年第一季度与FDA举行会议，以确定Buntanetap在帕金森病治疗中的进一步开发路径。Buntanetap也正被开发用于阿尔茨海默病、路易体痴呆及其他神经退行性疾病。

In

在

November 2024

2024年11月

, Cerevance

，Cerevance

announced the dosing of the first patient in its pivotal Phase III ARISE trial, evaluating solengepras as a potential adjunctive treatment for Parkinson's disease. Cerevance expects to report topline data in the first half of 2026. In

宣布了在其关键的III期ARISE试验中，首个患者已经开始接受给药，该试验旨在评估solengepras作为帕金森病潜在辅助治疗的效果。Cerevance预计将在2026年上半年报告初步数据。

December 2021

2021年12月

, UCB

，UCB

partnered with

与...合作

Novartis

诺华

to globally co-develop and co-commercialize

在全球范围内共同开发和共同商业化

UCB0599

UCB0599

, a pioneering alpha-synuclein misfolding inhibitor currently in Phase II clinical trials for Parkinson's disease.

，一种目前处于帕金森病二期临床试验的先驱α-突触核蛋白错误折叠抑制剂。

To know more about the number of competing drugs in development, visit @

要了解更多关于正在开发的竞争药物的数量，请访问 @

XADAGO/EQUFINA Market Positioning Compared to Other Drugs

XADAGO/EQUFINA与其他药物的市场定位比较

Key Milestones of XADAGO/EQUFINA

XADAGO/EQUFINA的关键里程碑

In

在

April 2020

2020年4月

, Newron Pharmaceutical

，纽罗制药公司

acknowledged that US WorldMeds, who held the US commercialization rights for the licensed drug, XADAGO, as a sub licensee of Zambon, had entered into a definitive agreement with Supernus Pharmaceuticals under which Supernus would acquire the CNS portfolio of US WorldMeds, including the US rights to XADAGO.

承认美国WorldMeds公司，作为Zambon的 sublicensee 持有授权药物XADAGO的美国商业化权利，已与Supernus Pharmaceuticals达成最终协议，根据该协议，Supernus将收购美国WorldMeds的中枢神经系统（CNS）产品组合，包括XADAGO的美国权利。

In

在

November 2019

2019年11月

, Eisai

，卫材

announced that it had launched the EQUFINA 50mg tablets for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in

宣布已推出EQUFINA 50mg片剂，用于改善在接受含左旋多巴药物治疗的帕金森病患者中的疗效减退现象。

Japan

日本

. Manufacturing and marketing approval of EQUFINA was obtained in

EQUFINA的生产和上市许可已获得

September 2019

2019年9月

.

。

In

在

April 2017

2017年4月

, Eisai Co., Ltd. and Meiji Seika Pharma

，卫材株式会社和明治制果药业

announced entering into a license agreement for the commercialization of safinamide (development code: ME2125) to treat Parkinson's disease in

宣布就商业化治疗帕金森病的沙芬酰胺（开发代码：ME2125）达成许可协议，

Japan

日本

and

和

Asia

亚洲

.

。

In

在

March 2017

2017年3月

, Newron Pharmaceuticals

，纽罗制药

announced the US FDA approval of XADAGO to treat Parkinson's disease as an add-on therapy to levodopa/carbidopa for patients experiencing 'off' episodes.

宣布美国FDA批准XADAGO用于治疗帕金森病，作为左旋多巴/卡比多巴的辅助疗法，针对出现“关闭”期症状的患者。

In

在

March 2016

2016年3月

, Zambon

，赞邦

announced a strategic agreement with US WorldMeds to commercialize Newron's lead compound, XADAGO, to treat Parkinson's disease in the US.

宣布与美国WorldMeds达成战略协议，将在美国商业化推广Newron的主打化合物XADAGO，用于治疗帕金森病。

In

在

February 2015

2015年2月

,

，

XADAGO was approved in the European Union as an add-on therapy to levodopa, alone or in combination with other Parkinson's medications, in mid-late stage PD patients with motor fluctuations.

XADAGO在欧洲联盟被批准作为左旋多巴的辅助治疗，单独使用或与其他帕金森病药物联合使用，用于中晚期帕金森病伴有运动波动的患者。

XADAGO/EQUFINA Patent Details

XADAGO/EQUFINA专利详情

XADAGO tablets are currently protected by three XADAGO patents with US patent numbers 8,076,515, 8,278,485, and 8,283,380, which expire between

XADAGO片剂目前受到三项XADAGO专利的保护，其美国专利号分别为8,076,515、8,278,485和8,283,380，这些专利将在以下时间到期：

June 2027

2027年6月

and

和

December 2028

2028年12月

and are listed in the FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. The company has a license agreement with Zambon S.p.A., Newron's partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO is under the 5-year FDA exclusivity period that expires on .

并被列入FDA出版的《经治疗等效性评估批准的药物产品》，通常称为橙皮书。该公司与Zambon S.p.A.（Newron的合作伙伴）就XADAGO专利签订了许可协议，作为一种新的化学实体，XADAGO正处于为期5年的FDA独占期，该期限于到期。

March 21, 2022

2022年3月21日

.

。

In

在

May 2017

2017年5月

, Zambon filed a worldwide patent under the patent number WO2017207587A1. The invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles, and a process for preparing them..

，Zambon在全球范围内申请了专利号为WO2017207587A1的专利。本发明涉及包含沙非那胺的药物组合物，更具体地，涉及包含所述活性成分或其药学上可接受的盐的掩味颗粒、包含所述颗粒的口服剂型以及制备它们的方法。

Discover how XADAGO/EQUFINA is shaping the Parkinson's disease treatment landscape @

发现XADAGO/EQUFINA如何塑造帕金森病治疗领域 @

XADAGO 50mg

XADAGO 50毫克

XADAGO/EQUFINA Market Dynamics

XADAGO/EQUFINA市场动态

XADAGO, marketed as EQUFINA in some regions (notably in

XADAGO，在某些地区（尤其是）作为EQUFINA销售，

South Korea

韩国

and

和

Japan

日本

), is a once-daily oral selective

），是一种每日一次的口服选择性药物

MAO-B inhibitor

单胺氧化酶B抑制剂

used as an add-on treatment for Parkinson's disease patients experiencing 'off' episodes while on a stable dose of levodopa. The drug's unique dual mechanism of action—MAO-B inhibition and modulation of glutamate release—offers both

用于帕金森病患者在稳定剂量左旋多巴治疗期间出现“关闭”期的辅助治疗。该药物独特的双重作用机制——MAO-B抑制和谷氨酸释放调节——提供了两者兼具的效果。

dopaminergic and non-dopaminergic effects

多巴胺能和非多巴胺能效应

, positioning it as a differentiated product in the PD adjunctive therapy landscape. This has helped it carve a niche in markets where patients are inadequately controlled by levodopa alone, particularly those in mid-to-late-stage PD.

，将其定位为PD辅助治疗领域中的差异化产品。这帮助它在左旋多巴单独控制不佳的患者市场中开辟了一个 niche，特别是那些处于中期至晚期的PD患者。

The global market dynamics for XADAGO/EQUFINA are shaped by a mix of

全球XADAGO/EQUFINA的市场动态由多种因素共同影响

competitive intensity, regional adoption trends, and payer dynamics

竞争强度、区域采用趋势和支付方动态

. In the U.S. and

. 在美国和

Europe

欧洲

, the drug has faced stiff competition from

，该药物面临来自

generic MAO-B inhibitors

通用MAO-B抑制剂

(like

（像

selegiline and rasagiline

司来吉兰和雷沙吉兰

) and newer Parkinson's disease therapies, including

）以及包括在内的较新的帕金森病疗法，

COMT inhibitors, dopamine agonists, and extended-release levodopa formulations

COMT抑制剂、多巴胺激动剂和缓释左旋多巴制剂

. Despite this, its favorable safety profile and once-daily dosing have supported its uptake in certain patient segments, especially in

尽管如此，其良好的安全性和每日一次的剂量支持了它在某些患者群体中的应用，尤其是在

Europe

欧洲

. Market penetration has been slower in the U.S. due to both

. 由于两方面的原因，美国市场的渗透速度较慢

reimbursement hurdles and physician preference

报销障碍和医生偏好

for more established adjunctive treatments.

对于更成熟的辅助治疗。

In

在

Asia

亚洲

, particularly

，尤其是

Japan

日本

and

和

South Korea

韩国

, EQUFINA has demonstrated stronger market performance thanks to

，EQUFINA凭借其更强的市场表现

focused commercial strategies

专注的商业策略

and a

和一个

high unmet need

高度未满足的需求

for effective 'off time' management.

为了有效管理“关闭时间”。

Meiji Seika Pharma and Eisai

明治制药和卫材

, the regional marketing partners, have successfully leveraged the drug's differentiated profile in clinician education, which has led to

，区域营销合作伙伴，成功利用了该药物在临床医生教育中的差异化特性，这导致了

growing adoption among neurologists

神经科医生的采用率不断提高

. In

。在

Japan

日本

, where the

，其中

aging population is rapidly expanding

老龄化人口正在迅速扩大

and

和

Parkinson's prevalence is rising

帕金森病的患病率正在上升。

, EQUFINA has benefited from both demographic tailwinds and formulary access.

，EQUFINA 受益于人口结构的有利因素和处方集的准入。

Looking ahead, the market outlook for XADAGO/EQUFINA depends on several strategic levers, including

展望未来，XADAGO/EQUFINA 的市场前景取决于几个战略杠杆，包括

lifecycle management, regional partnerships, and real-world evidence generation

生命周期管理、区域合作伙伴关系和真实世界证据生成

. The manufacturer's ability to expand into new geographies, secure favorable reimbursement, and differentiate against both generics and newer entrants will be critical. Moreover, as Parkinson's disease treatment moves toward more personalized approaches, XADAGO/EQUFINA may find sustained relevance in specific subpopulations, particularly those requiring a balance of efficacy and tolerability..

制造商拓展新地域、获得有利报销条件以及与仿制药和新进入者区分开来的能力将至关重要。此外，随着帕金森病治疗朝着更加个性化的方法发展，XADAGO/EQUFINA可能在特定亚群中保持持续的相关性，尤其是那些需要在疗效和耐受性之间取得平衡的患者群体。

Dive deeper to get more insight into XADAGO/EQUFINA's strengths & weaknesses relative to competitors @

深入研究以更深入地了解XADAGO/EQUFINA相对于竞争对手的优势和劣势 @

XADAGO/EQUFINA Market Drug Report

XADAGO/EQUFINA市场药物报告

Table of Contents

目录

1

1

Report Introduction

报告介绍

2

2

XADAGO/EQUFINA: Newron Pharmaceuticals/Eisai/Meiji Seika Pharma

XADAGO/EQUFINA：Newron Pharmaceuticals/Eisai/Meiji Seika Pharma

2.1

2.1

Product Overview

产品概述

2.2

2.2

Other Development Activities

其他开发活动

2.3

2.3

Clinical Development

临床开发

2.4

2.4

Clinical Trials Information

临床试验信息

2.5

2.5

Safety and Efficacy

安全性与有效性

2.6

2.6

Product Profile

产品概况

2.7

2.7

Market Assessment

市场评估

2.7.1

2.7.1

The 7MM Analysis

7MM分析

2.7.1.1

2.7.1.1

Cost Assumptions and Rebate

成本假设与回扣

2.7.1.2

2.7.1.2

Pricing Trends

价格趋势

2.7.1.3

2.7.1.3

Analogue Assessment

模拟评估

2.7.1.4

2.7.1.4

Launch Year and Therapy Uptake

上市年份与治疗吸收率

2.7.2

2.7.2

The United States Market Analysis

美国市场分析

2.7.3

2.7.3

EU4 and the United Kingdom Market Analysis

EU4 与英国市场分析

2.7.3.1

2.7.3.1

Germany

德国

2.7.3.2

2.7.3.2

France

法国

2.7.3.3

2.7.3.3

Italy

意大利

2.7.3.4

2.7.3.4

Spain

西班牙

2.7.3.5

2.7.3.5

UK

英国

2.7.4

2.7.4

Japan Market Analysis

日本市场分析

2.8

2.8

Market Drivers

市场驱动因素

2.9

2.9

Market Barriers

市场壁垒

2.10

2.10

SWOT Analysis

SWOT分析

3

3

Key Cross of Marketed Competitors of XADAGO/EQUFINA

XADAGO/EQUFINA上市竞争对手的关键交叉点

4

4

Key Cross of Emerging Competitors of XADAGO/EQUFINA

新兴竞争对手的关键交叉点：XADAGO/EQUFINA

Related Reports

相关报告

Parkinson's Disease Market

帕金森病市场

Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034

帕金森病市场洞察、流行病学与市场预测——2034年

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including

报告提供了对疾病的深入理解、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的帕金森病公司，包括

UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma

UCB生物制药有限公司，诺华，Annovis生物，Supernus制药公司，不列颠制药，Pharma

Two B

两个B

, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance,

三菱田边制药（NeuroDerm）、艾伯维、Cerevel Therapeutics、Cerevance、

among others.

其中包括。

Parkinson's Disease Pipeline

帕金森病管线

Parkinson's Disease Pipeline Insight – 2025

帕金森病研发管线洞察——2025

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including

报告提供了关于研发管线的全面见解，包括临床和非临床阶段产品的管线药物概况，以及关键的帕金森病公司，包括

Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., .

赛雷维尔治疗公司、抑制酶治疗公司、内拉利、佩普顿、百健、罗氏、脑神经治疗生物公司、莫达格、安娜维斯生物公司、生物维公司、联合神经科学有限公司、绿叶制药集团、艾伯维、UCB生物制药、因诺梅迪卡瑞士公司、综合研究实验室、H.伦贝克公司、上海现代制药股份有限公司、赛雷文斯贝塔公司、诺比利斯治疗公司、布鲁克治疗公司、台湾线粒体应用技术公司。

among others.

其中包括。

Cell and Gene Therapy in Parkinson's Disease Market

帕金森病的细胞和基因治疗市场

Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034

帕金森病的细胞和基因治疗市场洞察、流行病学和市场预测 - 2034

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including

报告深入介绍了帕金森病的疾病理解、历史和预测流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的细胞与基因治疗公司，包括

MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics,

MeiraGTx、Hope Biosciences、住友制药、Prevail Therapeutics、BlueRock Therapeutics、Voyager Therapeutics、

among others.

其中包括。

Parkinson's Disease Psychosis Market

帕金森病精神病市场

Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034

帕金森病精神病市场洞察、流行病学与市场预测——2034年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动力、市场障碍和关键的帕金森病精神病公司，包括

Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd,

住友制药美洲公司、范达制药、阿卡迪亚制药公司、大冢美国制药、伦贝克有限责任公司、爵士制药、阿尔凯斯特公司、山德士、希奥基因疗法、阿索万特科学有限公司，

among others.

其中。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

德尔维洞察是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来支持制药公司以提升其业绩。通过我们的基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

Shruti Thakur

info@delveinsight.com

info@delveinsight.com

+14699457679

+14699457679

Logo:

标志：

https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight商业研究有限公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用